The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS ...
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
3d
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results of the Phase ...
Roche announces phase III CENTERSTONE study of Xofluza significantly reduces the transmission of influenza viruses: Basel Friday, September 20, 2024, 09:00 Hrs [IST] Roche announc ...
Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...
US FDA approves Roche’s Ocrevus Zunovo to treat relapsing multiple sclerosis and PPMS: Basel Tuesday, September 17, 2024, 10:00 Hrs [IST] Roche announced that the United States ...
Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, had the pleasure to host a regional full day User meeting with 21 surgeons attending last ...
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that preclinical ...
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is the first time that any antiviral used in the treatment ...
A trust-building year Working in the language of ... relevant to technology accelerators for therapies and diagnostics at Genentech, where she received multiple awards, including two Innovation ...
Operable windows and fresh circulating air supplement the building’s energy efficient ... The Burnham Institute, Pfizer and Genentech. Robert’s depth of experience in both design and project ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback